NASDAQ · Biotechnology · USD

Bone Biologics Corporation (BBLG) Stock Analysis

Bone Biologics Corporation (BBLG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BBLG

$0.42

−$0.01 (−2.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BBLG with… →

BBLG Key Statistics

As of Oct 21, 2026

Trading

Open: $0.41
Previous Close: $0.43
Day's Range: 0.41–0.42
52-Week Range: 0.38–2.66
Volume: 15.65K
Beta: 0.57

Valuation

Market Cap: $1.09M
P/E Ratio: unprofitable
EPS (ttm): −1.37

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$3.11M
Shares Outstanding: 2.76M
1-Year Return: −82.86%

Dividend and dates

Avg Volume: 379.64K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BBLG closed at $0.42, −82.86% over 1 year.

Bone Biologics Corporation (BBLG) has a market capitalization of $1.09M.

In fiscal 2025, BBLG reported revenue of $0.00.

BBLG Stock Return by Calendar Year

Bone Biologics Corporation (BBLG) return since Oct 2021: what $10,000 became

1 year: $10,000 $1,714; −82.86%
5 years: $10,000 $0.65; −99.99%
Since Oct 2021: $10,000 $0.57; −99.99%

If you had invested $10,000 in Bone Biologics Corporation (BBLG) at the close on October 13, 2021, the earliest close on record here, it would have been worth $0.57 at the close on October 21, 2026: −99.99% in total, −85.70% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−30.84%−94.03%−91.03%−79.20%−74.29%−71.03%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−71.03%
2025	−74.29%
2024	−79.20%
2023	−91.03%
2022	−94.03%
2021 (partial year)	−30.84%

As of October 21, 2026.

BBLG Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$3.11M	—
2024	$0.00	−$4.11M	—
2023	$0.00	−$8.95M	—
2022	$0.00	−$1.48M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$3.23M	−$3.11M	—
2024	$0.00	—	−$4.22M	−$4.11M	—
2023	$0.00	—	−$9.43M	−$8.95M	—
2022	$0.00	$0.00	−$3.67M	−$1.48M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

The market values Bone Biologics Corporation (BBLG) at $1.09M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

The most recent close on file for BBLG is $0.42, dated October 21, 2026. That is −$0.01 (−2.33%) against the previous close. Over the past 52 weeks the price has ranged from $0.38 to $2.66. The latest close sits 10.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $3.11M. Earnings per share on a trailing basis come to −1.37.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −82.86%. Measured over 5 years, that is −85.47% a year compounded. Beta against the wider market is reported at 0.57. Daily returns over the trailing 5 years annualize to a volatility of 133.56%.

Growth & Income

No dividend is on file for BBLG.

Across the complete calendar years on file, 2025 returned −74.29% and 2022 returned −94.03%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −71.03% year to date.

Peer Comparison

Bone Biologics Corporation (BBLG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Bone Biologics Corporation	BBLG	$1.09M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Bone Biologics Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Bone Biologics Corporation

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Visit website →